Drug Profile
DHA-paclitaxel
Alternative Names: Paclitaxel-DHA conjugate; Paclitaxel-docosahexaenoic acid conjugate; TaxoprexinLatest Information Update: 04 Jan 2019
Price :
$50
*
At a glance
- Originator Luitpold Pharmaceuticals
- Class Antineoplastics; Paclitaxels; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours
Most Recent Events
- 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
- 08 May 2017 Luitpold Pharmaceuticals terminated a phase II trial in Liver cancer and biliary cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA as the sponsor suspended the development of the drug (IV-infusion) (NCT00422877)
- 19 Apr 2007 Discontinued - Phase-I/II for Solid tumours in United Kingdom (IV-infusion)